Stories making headlines today in the biopharma industry:
Amylyx Pharmaceuticals is on the precipice of a decisive Phase III trial aimed at resolving the controversy surrounding its ALS drug. The trial outcomes, to be revealed by the end of June, could be fundamental to the drug's fate, which was sanctioned by the FDA in 2022 after a single mid-level study.
Meanwhile, Bayer execs are resolute in preserving the company's current conglomerate composition amid calls for structural changes. Their priority is handling existing issues in the pharma, consumer health, and crop science departments. As the company manoeuvres through challenges over the next couple of years, it anticipates trimming roles deemed as obstructions.
Regenxbio has shed light on promising early biomarker results for a Duchenne muscular dystrophy patient treated with a high dose of its gene therapy. The results suggest a considerable decrease in creatinine kinase levels and efficient dysfermin expression courtesy of the treatment. In anticipation of more positive results, Regenxbio expects to kick off a key study later this year, targeting a broader age bracket of boys.
In another exciting development, Alnylam Pharmaceuticals, in partnership with Roche, has marked a second clinical victory by successfully lowering blood pressure in the Phase II hypertension trial with its RNAi therapy. The collaboration with Roche began in July and continues to note progress.
On the corporate activity front, while BridgeBio publicised plans to raise $250 million via a stock sale, Bayer has revealed the purchase of European rights to acoramidis, BridgeBio's proposed treatment drug for ATTR amyloidosis with cardiomyopathy.
In its continued efforts for improvement, Bayer has indicated no intention of breaking up its pharma, consumer, and crop science divisions. The focus remains fixed on remedying the areas in need and strategic planning for the future growth and flexibility of the company.
#pharma #biotech #topstories #biodatastudio
